GlassScriptPhysician profile
Johnny C L Yu
NPI 1649203571
$2,372.59
in general payments reported to CMS, 2019-2025
18 companies · $72.48 in 2025
The $72.48 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $115 · 2021: $110 · 2022: $673 · 2023: $631 · 2024: $312 · 2025: $72.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $377.79 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $360.91 | 2023-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $342.35 | 2019-2024 | |
| Novastep INC. | $280.20 | 2022 | |
| Boston Scientific Corporation | $278.56 | 2019-2022 | |
| Amarin Pharma, INC. | $227.54 | 2019-2021 | |
| Amgen INC. | $96.98 | 2024-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $80.84 | 2019-2024 | |
| Esperion Therapeutics, INC. | $75.06 | 2023-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.56 | 2019-2021 | |
| American Regent | $49.32 | 2023 | Injectafer |
| Pfizer INC. | $35.41 | 2020-2022 | |
| Allergan, INC. | $20.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.62 | 2023 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $15.93 | 2023 | Inpefa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.43 | 2023 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $13.85 | 2022 | |
| Infobionic, INC | $13.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.